Loading…
Loading…
WHTCF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for WHTCF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for WHTCF and 80,000+ other tickers.
See exactly how WHTCF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WHTCF and 80,000+ other tickers.
WELL Health Technologies Corp. operates as a digital healthcare enterprise primarily serving medical professionals across Canada, the United States, and globally. The company delivers a comprehensive range of omni-channel patient solutions. These encompass foundational primary care, various allied health services such as physiotherapy, occupational therapy, chiropractic care, dietary advice, mental health support, and sleep-related treatments. Furthermore, WELL provides specialized medical attention, including access to gastroenterologists, along with diagnostic testing for conditions…
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announces it has closed its previously announced inaugural private placement offering (the "Offering") of $150 million aggregate principal amount of 6.875% senior unsecured notes due July 15, 2031 (the "Notes"). The Notes were issued at par under a trust indenture and are direct senior unsecured obligations of WELL and rank equally in right of payment with all other present and future senior unsecured indebtedness of the Company.
WELL has priced its inaugural offering of $150 million of senior unsecured notes due 2031, bearing interest at 6.875% per annum. Net proceeds will be used to fully repay WELL's convertible debentures due December 2026 and for general corporate purposes.
Not for distribution to United States news wire services or for dissemination in the United States. WELLSTAR is expected to become a publicly listed company through a TSXV listing, supported by a Concurrent Financing with gross proceeds of approximately $50 million anchored by strong institutional subscription from a large Canadian bank-owned asset manager and continued support from existing shareholders.
Not for distribution to United States news wire services or for dissemination in the United States. WELLSTAR is expected to become a publicly listed company through a TSXV listing, supported by a Concurrent Financing with gross proceeds of approximately $50 million anchored by strong institutional subscription from a large Canadian bank-owned asset manager and continued support from existing shareholders.
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general and special meeting held June 16, 2026 (the "Meeting"), all of the nominees for election as directors of the Company referred to in its notice of meeting and information circular dated May 8, 2026 for the Meeting were elected. A total of 90,692,992 common shares representing 35.50% of the outstanding common shares of the Company were voted by proxy at the Meeting.